Minerva Neuroscie (NERV)

$2.56 -0.27 (-9.43%)
Market Cap 15.24M
Revenue (ttm) 0.00
Net Income (ttm) 1.44M
EPS (ttm) N/A
PE Ratio 1.45
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 288,201
Avg Vol 280,496
Day's Range N/A - N/A
Shares Out 6.99M
Stochastic %K 63%
Beta -0.30
Analysts Hold
Price Target $4.00

Company Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neur...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 600 7373
Address:
1500 District Avenue, Burlington, United States
skyrockets_Inc
skyrockets_Inc Oct. 9 at 6:08 PM
$BOLT first was $GLTO, then $NERV, next $BOLT on the low float action ~1.92m OS, $15/share in cash, 30% institutional ownership w/ 5% insider ownership. Tang owns 10% . BDC-3142 data due in Q3 2026 and partnership announcement possibility for BDC-3042 anytime before then. Loading has been happening consistently the past ~2 weeks can see it in the volume chart.
1 · Reply
BOXLinvestor
BOXLinvestor Oct. 9 at 4:46 AM
$NERV Minerva Neurosciences (stock volume 10-08-25) 2.83 +29.8% | volume 5,292,313 | 90-day avg 63,829 × 82.9
0 · Reply
StockScanners
StockScanners Oct. 9 at 3:07 AM
$NERV reached 3.29
0 · Reply
SpudZone
SpudZone Oct. 8 at 9:36 PM
$AMBO This will be a nice SHORT tmrw... similar to my $NERV 40% short last night
0 · Reply
eagleeye11
eagleeye11 Oct. 8 at 7:40 PM
$NERV $$ let's get the party started
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 8 at 6:09 PM
Watch MSN rest of the week volume ascending, only 50k left to borrow, golden cross on the daily, massive volume,and 52 week high breakout. for $1.00/1.25/2.00+ $UPC $RKDA $NXL $NERV
0 · Reply
Invest2live
Invest2live Oct. 8 at 5:33 PM
$BITF 280% already; congrats 🎉 🎊🎈 Checkout $NERV and $FORA
1 · Reply
PharmaExpert
PharmaExpert Oct. 8 at 5:26 PM
$AKBA, $XBIO, $ACXP, $UPC, $NERV 🔥🔥🔥🔥🔥
1 · Reply
BOXLinvestor
BOXLinvestor Oct. 8 at 4:23 PM
$NERV Minerva Neurosciences (stock volume 10-07-25) 2.86 +31.2% | volume 3,812,901 | 90-day avg 63,829 × 59.7
0 · Reply
jamestocklover
jamestocklover Oct. 8 at 4:20 PM
$FPAY $1 BREAK IS COMING, THEN FOMO. $140M REVENUE. MMULTIBAGGER. LOW FLOAT. $5+ 🔥🚀💯 $BURU 800M volume toward $1 $ADAP nice uptrend. $NERV making an up move $PCSA 100M volume and nice move
0 · Reply
Latest News on NERV
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

Aug 14, 2025, 4:35 PM EDT - 7 weeks ago

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025, 7:30 AM EDT - 5 months ago

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Feb 25, 2025, 7:00 AM EST - 8 months ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Nov 5, 2024, 7:30 AM EST - 1 year ago

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

May 1, 2024, 7:30 AM EDT - 1 year ago

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Feb 27, 2024, 8:14 AM EST - 1 year ago

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Feb 22, 2024, 7:00 AM EST - 1 year ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Nov 7, 2023, 7:30 AM EST - 2 years ago

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Minerva Neurosciences: There's Probably Time For One More Rally

Aug 23, 2023, 4:05 AM EDT - 2 years ago

Minerva Neurosciences: There's Probably Time For One More Rally

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Jun 28, 2023, 8:30 AM EDT - 2 years ago

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

May 19, 2023, 5:34 PM EDT - 2 years ago

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

May 15, 2023, 11:26 AM EDT - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

May 15, 2023, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

May 10, 2023, 8:00 AM EDT - 2 years ago

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

May 8, 2023, 8:30 AM EDT - 2 years ago

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 11:31 AM EST - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Mar 8, 2023, 7:30 AM EST - 2 years ago

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Mar 1, 2023, 8:30 AM EST - 2 years ago

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Nov 9, 2022, 10:02 AM EST - 3 years ago

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Nov 9, 2022, 8:00 AM EST - 3 years ago

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Nov 2, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Minerva Neurosciences to request meeting with FDA about schizophrenia drug

Oct 17, 2022, 8:51 AM EDT - 3 years ago

Minerva Neurosciences to request meeting with FDA about schizophrenia drug

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Oct 17, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Sep 9, 2022, 4:05 PM EDT - 3 years ago

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Aug 22, 2022, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

May 4, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Apr 7, 2022, 1:01 PM EDT - 3 years ago

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Apr 7, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

Mar 1, 2022, 7:30 AM EST - 3 years ago

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Feb 28, 2022, 8:30 AM EST - 3 years ago

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 2:11 PM EST - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Nov 8, 2021, 7:30 AM EST - 4 years ago

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Nov 3, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Nov 1, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Minerva Neurosciences Announces Promotion of Geoff Race to President

Oct 11, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces Promotion of Geoff Race to President

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Sep 30, 2021, 10:32 AM EDT - 4 years ago

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Sep 30, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Aug 2, 2021, 12:19 PM EDT - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Aug 2, 2021, 7:30 AM EDT - 4 years ago

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Jul 26, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

Jun 10, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

May 28, 2021, 8:00 AM EDT - 4 years ago

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript

May 12, 2021, 4:40 PM EDT - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

May 12, 2021, 7:30 AM EDT - 4 years ago

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

May 11, 2021, 4:15 PM EDT - 4 years ago

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

May 5, 2021, 5:10 PM EDT - 4 years ago

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q4 2020 Results - Earnings Call Transcript

Mar 8, 2021, 12:35 PM EST - 4 years ago

Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q4 2020 Results - Earnings Call Transcript

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

Mar 8, 2021, 7:30 AM EST - 4 years ago

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

skyrockets_Inc
skyrockets_Inc Oct. 9 at 6:08 PM
$BOLT first was $GLTO, then $NERV, next $BOLT on the low float action ~1.92m OS, $15/share in cash, 30% institutional ownership w/ 5% insider ownership. Tang owns 10% . BDC-3142 data due in Q3 2026 and partnership announcement possibility for BDC-3042 anytime before then. Loading has been happening consistently the past ~2 weeks can see it in the volume chart.
1 · Reply
BOXLinvestor
BOXLinvestor Oct. 9 at 4:46 AM
$NERV Minerva Neurosciences (stock volume 10-08-25) 2.83 +29.8% | volume 5,292,313 | 90-day avg 63,829 × 82.9
0 · Reply
StockScanners
StockScanners Oct. 9 at 3:07 AM
$NERV reached 3.29
0 · Reply
SpudZone
SpudZone Oct. 8 at 9:36 PM
$AMBO This will be a nice SHORT tmrw... similar to my $NERV 40% short last night
0 · Reply
eagleeye11
eagleeye11 Oct. 8 at 7:40 PM
$NERV $$ let's get the party started
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 8 at 6:09 PM
Watch MSN rest of the week volume ascending, only 50k left to borrow, golden cross on the daily, massive volume,and 52 week high breakout. for $1.00/1.25/2.00+ $UPC $RKDA $NXL $NERV
0 · Reply
Invest2live
Invest2live Oct. 8 at 5:33 PM
$BITF 280% already; congrats 🎉 🎊🎈 Checkout $NERV and $FORA
1 · Reply
PharmaExpert
PharmaExpert Oct. 8 at 5:26 PM
$AKBA, $XBIO, $ACXP, $UPC, $NERV 🔥🔥🔥🔥🔥
1 · Reply
BOXLinvestor
BOXLinvestor Oct. 8 at 4:23 PM
$NERV Minerva Neurosciences (stock volume 10-07-25) 2.86 +31.2% | volume 3,812,901 | 90-day avg 63,829 × 59.7
0 · Reply
jamestocklover
jamestocklover Oct. 8 at 4:20 PM
$FPAY $1 BREAK IS COMING, THEN FOMO. $140M REVENUE. MMULTIBAGGER. LOW FLOAT. $5+ 🔥🚀💯 $BURU 800M volume toward $1 $ADAP nice uptrend. $NERV making an up move $PCSA 100M volume and nice move
0 · Reply
topstockalerts
topstockalerts Oct. 8 at 4:14 PM
$NERV Looking good!
0 · Reply
ISHARETRADEALERTS
ISHARETRADEALERTS Oct. 8 at 3:38 PM
$NERV lets get NHOD Filled more 3.01
0 · Reply
vanderuk
vanderuk Oct. 8 at 3:35 PM
$NERV no news - retail pump, barely any volume, will dump back to 2
1 · Reply
ISHARETRADEALERTS
ISHARETRADEALERTS Oct. 8 at 3:35 PM
$NERV added 3.03 day trade 3.50s first pt
0 · Reply
Invest2live
Invest2live Oct. 8 at 3:32 PM
$NERV 26% already; congrats 🎊🎉🙏🎈 Checkout $CUE and $GOVX for longs.
0 · Reply
Negroni
Negroni Oct. 8 at 3:32 PM
$NERV here we go trader incoming GLTO move imminent…
0 · Reply
Hunterdownunder
Hunterdownunder Oct. 8 at 3:30 PM
$NERV somebody nose something
1 · Reply
Noble_Trades
Noble_Trades Oct. 8 at 3:29 PM
Really like this curve I'm seeing on $NERV RN. Volume as well. Crossing VWAP. I'm jumping in for a trade. Best thing going RN is $PAVS, this morning's action combined with compliance news coming on Friday this doubles with a short hold. Watching $BULL for dips. Checking out $POET chart maybe a reversal coming.
0 · Reply
Jaybird99
Jaybird99 Oct. 8 at 3:16 PM
$NERV took some time but I'll take it
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 8 at 2:52 PM
$NERV just soared 5% higher to 27% (~4Mv) in the last few minutes, follow for more volatility.
0 · Reply
MASTER_CHIEF__117
MASTER_CHIEF__117 Oct. 8 at 2:04 PM
$NERV busting out. sitrep - PT 6.00 gap up at 5.80… compliance and accelerated program.
0 · Reply
topstockalerts
topstockalerts Oct. 8 at 1:32 PM
$NERV sector heating up.. stay tuned!
0 · Reply